Skip to main content

With Top Executives in Place, EraGen Sets Sights on Commercializing Tools

NEW YORK, Aug. 23 - With its functional-proteomics tools and nucleic-acid diagnostics ready to roll, EraGen Biosciences has completed building up its executive-management team.


Yesterday the company said Samraat Raha, former vice president of discovery services at Incyte Genomics, would be its first chief business officer, and earlier this month it hired Gary Madsen, a former manager at Abbott Labs, to be chief technical officer.

EraGen had named its first president and CEO, former GlaxoSmithKline executive Irene Hrusovsky, in February.


The firm said it is close to naming a new vice president of finance and a vice president of technical development and manufacturing.


EraGen's technology includes the Master Catalog proteomics data-mining and -analysis tool, the MultiCode and GeneCode genotyping tools, and the EraCode molecular recognition technology.


"Our next step is really to try and coordinate all the new people, try to work on the new goals that we have set," said Carly Owen, Hrusovsky's assistant.


It was not immediately clear when the company would begin rolling out its technology.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.